Patient P-02009

Synthetic patientMETA-24 · Day 160 · 75+ · M · baseline S08Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Unstable

GI state

Stable

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

49%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S08
Day 62 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 122 CR-01 recommended — Clinician Review CR-01
Day 123 Patient accepted — Started CR-01 in the companion
Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 62.

Primary contributors, last 14 days

Toxicity+20
Inflammatory activity+8
Nutritional resilience-5
Treatment adherence-5
GI instability-2

What helped?

Clinician Review CR-01Day 122
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

63%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

28 min

worsening · -9.0 vs previous 14 d

Sleep duration

Wearable

5.5 h

stable · +0.0 vs previous 14 d

Energy level

Daily log

3.5/10

worsening · -0.4 vs previous 14 d

Steps

Wearable

3,229

worsening · -835 vs previous 14 d

GI burden

Companion

45.2/100

worsening · +5.3 vs previous 14 d

Adherence

Companion

72.6 %

worsening · -10.6 vs previous 14 d

Sleep quality

Wearable

23.3/100

worsening · -2.1 vs previous 14 d

Glucose, CGM daily mean

CGM

141 mg/dL

stable · +0.6 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 48 from the failing basin, 45 from restoration.

Good elements to keep

Clinician Review CR-01
intervention · steering +26.8
Protein (supports)
perturbation · steering +6.6
Protein
supporter · GI -3.9 next day

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
FUT2 non-secretor
hidden · steering -10.6
Bacteroides fragilis elevated
hidden · steering -7.4
IL6 high-expression variant
hidden · steering -7.3
Histamine load
detractor · GI +3.5 next day
Ultra-processed food
detractor · GI +2.4 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-3.9supporter · 95%
Histamine load
+3.5detractor · 95%
Ultra-processed food
+2.4detractor · 88%
Alcohol
+2.1detractor · 80%
Dietary fat load
+1.7detractor · 63%
Insoluble fibre
-1.1no signal · 37%
Simple carbohydrates
-0.3no signal · 15%
Caffeine
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 45 and rising
- WearableSleep 5.5 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 56
Autonomic recovery ↓40
- Wearable3,229 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 60

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 48 ms
Sleep: 5.1 h
Steps: 3,188
Resting HR: 67 bpm

Daily log: GI score 45, nutritional resilience 38, adherence 73.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02233	44%	S16	CR-01	improved	66
P-02054	43%	S01	CR-01	improved	57
P-02321	41%	S17	GI-04	improved	54
P-02154	38%	S16	CR-01	improved	57
P-02398	38%	S06	GI-04	improved	63
P-02185	36%	S14	GI-04	improved	51
P-02334	36%	S04	GI-04	improved	66
P-02433	36%	S07	GI-04	improved	61
P-02240	35%	S20	GI-04	improved	57
P-02051	34%	S14	GI-04	improved	45
P-02103	34%	S14	GI-04	improved	46
P-02106	34%	S14	GI-04	improved	44